Solid Biosciences Inc. SLDB
Updated: 9 Aug 2026
No signal published yet
We already track Solid Biosciences and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Solid Biosciences Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Solid Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, Solid Biosciences reported its second quarter 2026 financial results and provided a business update. The company highlighted the initiation of dosing in the Phase 3 IMPACT DUCHENNE clinical trial evaluating SGT-003 and reported cash and available-for-sale securities of $377.7 million as of June 30, 2026. Solid also announced plans to meet with the FDA in late Q4 2026 to discuss a potential accelerated approval pathway for SGT-003.
What Firelda Watch includes for Solid Biosciences Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Solid Biosciences Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Solid Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more